ROCKVILLE, MARYLAND , August 24, 2026 — The global solid tumor testing market reached a valuation of USD 30.7 billion in 2025. Demand is projected to expand from USD 32.9 billion in 2026 to USD 65.9 billion by 2036, recording a compound annual growth rate (CAGR) of 7.2% over the ten-year forecast period.
According to market data published by Fact.MR, the industry represents an absolute expansion opportunity of USD 33.0 billion between 2026 and 2036.
Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15842
Executive Summary & Key Findings
Solid tumor testing products and services are utilized by healthcare providers to identify molecular and genomic signals within solid tumors to guide diagnosis, therapy selection, and disease monitoring.
• Primary Market Driver: The necessity for genetic testing workflows that directly connect tumor types and specific biomarker results with actionable treatment decisions.
• Core Product Dominance: Genetic testing products lead the market share, driven by widespread adoption of tumor genotyping across oncology centers.
• Dominant Application: Breast cancer testing represents the largest application segment due to routine receptor and HER2 mutation profiling.
• Leading Technology: Next-Generation Sequencing (NGS) controls the highest technology share owing to its ability to consolidate multi-biomarker evaluation into a single workflow.
Market Growth Drivers
Fact.MR identifies several primary quantitative growth factors accelerating market expansion from 2026 to 2036:
1. Genetic Testing Specification Pull (+1.8% CAGR Impact): Short-term adoption (